Nuveen Asset Management LLC Has $13.60 Million Holdings in Twist Bioscience Co. (NASDAQ:TWST)

Nuveen Asset Management LLC increased its position in Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 43.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 292,645 shares of the company's stock after buying an additional 89,170 shares during the period. Nuveen Asset Management LLC owned 0.49% of Twist Bioscience worth $13,599,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Lazard Asset Management LLC grew its holdings in Twist Bioscience by 39.0% during the fourth quarter. Lazard Asset Management LLC now owns 27,881 shares of the company's stock valued at $1,295,000 after purchasing an additional 7,827 shares during the last quarter. Graham Capital Management L.P. grew its holdings in Twist Bioscience by 25.0% during the fourth quarter. Graham Capital Management L.P. now owns 17,428 shares of the company's stock valued at $810,000 after purchasing an additional 3,483 shares during the last quarter. D. E. Shaw & Co. Inc. grew its holdings in Twist Bioscience by 1,085.9% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 107,268 shares of the company's stock valued at $4,985,000 after purchasing an additional 98,223 shares during the last quarter. Deutsche Bank AG boosted its position in shares of Twist Bioscience by 8.8% in the fourth quarter. Deutsche Bank AG now owns 159,752 shares of the company's stock valued at $7,424,000 after acquiring an additional 12,940 shares during the period. Finally, Deerfield Management Company L.P. Series C boosted its position in shares of Twist Bioscience by 1.7% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 23,827 shares of the company's stock valued at $1,107,000 after acquiring an additional 403 shares during the period.

Insider Activity at Twist Bioscience

In other Twist Bioscience news, COO Patrick John Finn sold 1,877 shares of the business's stock in a transaction dated Wednesday, May 21st. The stock was sold at an average price of $29.75, for a total transaction of $55,840.75. Following the completion of the sale, the chief operating officer now directly owns 240,783 shares of the company's stock, valued at approximately $7,163,294.25. The trade was a 0.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Paula Green sold 918 shares of the business's stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $40.91, for a total transaction of $37,555.38. Following the transaction, the senior vice president now owns 130,912 shares of the company's stock, valued at approximately $5,355,609.92. This represents a 0.70% decrease in their position. The disclosure for this sale can be found here. Insiders sold 26,850 shares of company stock valued at $974,764 over the last ninety days. 3.01% of the stock is owned by insiders.

Twist Bioscience Stock Performance

TWST stock traded up $0.56 during midday trading on Thursday, hitting $28.89. The stock had a trading volume of 1,192,171 shares, compared to its average volume of 979,604. The firm has a market capitalization of $1.73 billion, a price-to-earnings ratio of -8.55 and a beta of 2.54. The stock has a 50-day simple moving average of $35.90 and a 200 day simple moving average of $42.50. Twist Bioscience Co. has a 52 week low of $27.12 and a 52 week high of $60.90. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). The company had revenue of $92.79 million for the quarter, compared to the consensus estimate of $92.00 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. As a group, equities research analysts anticipate that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently weighed in on TWST. Guggenheim reissued a "buy" rating and issued a $50.00 price objective on shares of Twist Bioscience in a research report on Tuesday, May 6th. Barclays reduced their price objective on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a research report on Thursday, April 10th. Robert W. Baird reduced their price objective on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating for the company in a research report on Tuesday, May 6th. Scotiabank reissued an "outperform" rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. Finally, JPMorgan Chase & Co. reduced their price objective on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $50.40.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.